Literature DB >> 26884898

Tibetan medicine "RNSP" in treatment of Alzheimer disease.

Jing-Ming Shi1, Xue He1, Hui-Juan Lian1, Dong-Ya Yuan1, Qun-Ying Hu1, Zheng-Qi Sun1, Yan-Song Li1, Yu-Wen Zeng1.   

Abstract

Alzheimer disease (Alzheimer Disease, AD) is one of the most common type in senile dementia. Its main pathological features were that a large number of senile plaques gathered in brain extracellular and tangles fibrosis appeared in nerve cells. Currently, the pathogenesis of AD is still uncertain, and scale investigation and combined brain CT, MRI data were analyzed mainly for clinical diagnosis. Mitigation and improvement of the nervous system activity to interfere with the subsequent behavior of the patients are the main methods for treatment. In clinical no drug can really prevent and cure AD. From the view point of Tibetan medicine studies, Tibetan medicine RNSP has effect on improving memory and repairing the neurons in the brain. In this study, we combined the characteristics of AD pathology, pathogenesis, diagnosis and treatment methods to explore the feasibility of Tibetan medicine RNSP for the treatment of AD to provide new ideas for the diagnosis and treatment of AD.

Entities:  

Keywords:  Alzheimer disease (AD); Aβ protein; Tibetan medicine RNSP

Year:  2015        PMID: 26884898      PMCID: PMC4723743     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  17 in total

Review 1.  Modern care for patients with Alzheimer disease: rationale for early intervention.

Authors:  Katherine E Galluzzi; Denah M Appelt; Brian J Balin
Journal:  J Am Osteopath Assoc       Date:  2010-09

2.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

Review 3.  Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity.

Authors:  Vello Tõugu; Ann Tiiman; Peep Palumaa
Journal:  Metallomics       Date:  2011-02-25       Impact factor: 4.526

Review 4.  Tau oligomers and tau toxicity in neurodegenerative disease.

Authors:  Sarah M Ward; Diana S Himmelstein; Jody K Lancia; Lester I Binder
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

Review 5.  Epidemiology of Alzheimer disease.

Authors:  Christiane Reitz; Carol Brayne; Richard Mayeux
Journal:  Nat Rev Neurol       Date:  2011-02-08       Impact factor: 42.937

6.  Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls.

Authors:  Thomas J Esparza; Hanzhi Zhao; John R Cirrito; Nigel J Cairns; Randall J Bateman; David M Holtzman; David L Brody
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 7.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

Review 10.  The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

Authors:  Kaj Blennow; Henrik Zetterberg
Journal:  Med Clin North Am       Date:  2013-02-01       Impact factor: 5.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.